Not provided
Not provided
Not provided
Not provided
Funding delayed beyond acceptable start date
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biotechnology and Biological Sciences Research Council | OTHER |
| Quercegen Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of acute isoquercetin supplementation, aspirin, and isoquercetin/aspirin combination on platelet aggregation, blood pressure and vasculat stiffness (eg digital volume pulse), as well as investigating the plasma accumulation and urine excretion profiles of quercetin.
Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2012, approximately 17.5 million people worldwide died from CVD, representing 31% of global death. Flavonoids are a class of plant secondary metabolites, functioning in the plant to aid in growth. These compounds are found in diets worldwide, and many cohort studies have demonstrated the protective effect of diets high in flavonoids against CVD events, with some studies showing flavonoid intake inversely associated with CV event risk, CV non-fatal events and all-cause mortality. One consistent issue with quercetin as a dietary flavonoid is the plasma concentrations it is able to reach are not always sufficient to provide a protective effect. Therefore, supplementation or pharmacological intervention with flavonoids may offer a solution. Supplementation with isoquercetin, the 3-O-glucoside of quercetin, offers the potential for much higher plasma concentrations of quercetin and its metabolites than dietary sources can offer, with associated increased inhibitory, anti-platelet effects. It must therefore be addressed whether isoquercetin supplementation can effectively reduce platelet function ex vivo, measured by aggregation and closure time, as well as improve vascular function, measured through blood pressure (BP) and vascular stiffness (eg digital volume pulse (DVP)).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vehicle control | Placebo Comparator | Subjects will consume
|
|
| Isoquercetin | Experimental | Subjects will consume
|
|
| Aspirin | Active Comparator | Subjects will consume
|
|
| Isoquercetin plus Aspirin | Experimental | Subjects will consume
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vehicle control | Drug | Described in arm |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in platelet aggregation | Acute Study: measured at -60 (baseline), 120, 240 and 360min |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Closure Time (CT), measured with a Platelet Function Analyzer (PFA) | Acute study: measured at -60 (baseline), 120, 240 and 360min | |
| Change from baseline in blood pressure (systolic pressure, diastolic pressure and pulse pressure) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Julie A Lovegrove, BSc PhD RNutr | University of Reading | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Reading | Reading | Berkshire | RG6 6AP | United Kingdom |
Data will be averaged (some will also be normalized) before publishing, IPD (Individual Participant Data) will not be made available
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C016527 | isoquercitrin |
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Isoquercetin | Drug | Described in arm |
|
|
| Aspirin | Drug | Described in arm |
|
|
| Isoquercetin plus Aspirin | Drug | Described in arm |
|
|
| Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min |
| Change from baseline in arterial stiffness measured by digital volume pulse - stiffness index | Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min |
| Change from baseline in arterial stiffness measured by digital volume pulse - reflection index | Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min |
| Change from baseline in total plasma quercetin concentration (micromolar) | Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min |
| Change from baseline in total urine quercetin concentration (micromolar) | Acute study: measured at 0 (baseline),120, 240 and 360min |
| D006841 |
| Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |